Strategies in cancer vaccines development

International Journal for Parasitology

Volumn 33, Issue 5-6, 2003, Pages 597-613

  Cunto Amesty, Gina ^a   Monzavi Karbassi, Behjatolah ^a   Luo, Ping ^a   Jousheghany, Fariba ^a   Kieber Emmons, Thomas ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cancer vaccine; Carbohydrate; Peptide mimotope; Tumour immunotherapy

Indexed keywords

CANCER VACCINE; IMMUNOGLOBULIN M; LECTIN; PEPTIDE LIBRARY;

VACCINATION;

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; AUTOIMMUNITY; BACTERICIDAL ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL ADHESION; CELL SURVIVAL; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; MOLECULAR MIMICRY; NATURAL KILLER CELL; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; REVIEW; SECONDARY IMMUNE RESPONSE; TH1 CELL; VACCINATION;

EID: 0038354914     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(03)00054-7     Document Type: Review

References (164)

1. Abdel-Motal U., Berg L., Rosen A., Bengtsson M., Thorpe C.J., Kihlberg J., Dahmen J., Magnusson G., Karlsson K.A., Jondal M. Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur. J. Immunol. 26:1996;544-551.
2. Agadjanyan M., Luo P., Westerink M.A., Carey L.A., Hutchins W., Steplewski Z., Weiner D.B., Kieber-Emmons T. Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat. Biotechnol. 15:1997;547-551.
3. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E.K., Berzofsky J.A. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc. Natl. Acad. Sci. USA. 99:2002;13020-13025.
4. Alfonso M., Diaz A., Hernandez A.M., Perez A., Rodriguez E., Bitton R., Perez R., Vazquez A.M. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168:2002;2523-2529.
5. Apostolopoulos V., Lofthouse S.A., Popovski V., Chelvanayagam G., Sandrin M.S., McKenzie I.F. Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nat. Biotechnol. 16:1998;276-280.
6. Apostolopoulos V., Osinski C., McKenzie I.F. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med. 4:1998;315-320.
7. Apostolopoulos V., Sandrin M.S., McKenzie I.F. Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. J. Mol. Med. 77:1999;427-436.
8. Apostolopoulos V., Sandrin M.S., McKenzie I.F. Mimics and cross reactions of relevance to tumour immunotherapy. Vaccine. 18:1999;268-275.
9. Appelmelk B.J., Negrini R., Moran A.P., Kuipers E.J. Molecular mimicry between Helicobacter pylori and the host. Trends Microbiol. 5:1997;70-73.
10. Appelmelk B.J., Simoons S.I., Negrini R., Moran A.P., Aspinall G.O., Forte J.G., De Vries T., Quan H., Verboom T., Maaskant J.J., Ghiara P., Kuipers E.J., Bloemena E., Tadema T.M., Townsend R.R., Tyagarajan K., Crothers J.J., Monteiro M.A., Savio A., DeGraaff J. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect. Immun. 64:1996;2031-2040.
11. Behar S.M., Podrebarac T.A., Roy C.J., Wang C.R., Brenner M.B. Diverse TCRs recognize murine CD1. J. Immunol. 162:1999;161-167.
12. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., Gallino G., Piris A., Cattelan A., Lazzari I., Carrabba M., Scita G., Santantonio C., Pilla L., Tragni G., Lombardo C., Arienti F., Marchiano A., Queirolo P., Bertolini F., Cova A., Lamaj E., Ascani L., Camerini R., Corsi M., Cascinelli N., Lewis J.J., Srivastava P., Parmiani G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20:2002;4169-4180.
13. Ben-Yedidia T., Beignon A.S., Partidos C.D., Muller S., Arnon R. A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. Mol. Immunol. 39:2002;323-331.
14. Bhattacharya-Chatterjee M., Chatterjee S.K., Foon K.A. Anti-idiotype antibody vaccine therapy for cancer. Expert Opin. Biol. Ther. 2:2002;869-881.
15. Bremer E.G., Levery S.B., Sonnino S., Ghidoni R., Canevari S., Kannagi R., Hakomori S. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBR1 expressed in normal and neoplastic epithelial cells of human mammary gland. J. Biol. Chem. 259:1984;14773-14777.
16. Brossart P., Wirths S., Stuhler G., Reichardt L.V., Kanz L., Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccination with peptide-pulsed dendritic cells. Blood. 96:2000;3102-3108.
17. Brutkiewicz R.R., Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit. Rev. Oncol. Hematol. 41:2002;287-298.
18. Burchell J.M., Mungul A., Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia. 6:2001;355-364.
19. Castano A.R., Tangri S., Miller J.E., Holcombe H.R., Jackson M.R., Huse W.D., Kronenberg M., Peterson P.A. Peptide binding and presentation by mouse CD1. Science. 269:1995;223-226.
20. Cerchia L., Hamm J., Libri D., Tavitian B., de Franciscis V. Nucleic acid aptamers in cancer medicine. FEBS Lett. 528:2002;12-16.
21. Chen L. Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. Curr. Opin. Immunol. 11:1999;219-222.
22. Conry R.M., Allen K.O., Lee S., Moore S.E., Shaw D.R., LoBuglio A.F. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. 6:2000;34-41.
23. Crowe N.Y., Smyth M.J., Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:2002;119-127.
24. Cunto-Amesty G., Dam T.K., Luo P., Monzavi-Karbassi B., Brewer C.F., Van Cott T.C., Kieber-Emmons T. Directing the immune response to carbohydrate antigens. J. Biol. Chem. 30:2001;30.
25. Cunto-Amesty G., Luo P., Monzavi-Karbassi B., Lees A., Kieber-Emmons T. Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. Vaccine. 19:2001;2361-2368.
26. Curti A., Parenza M., Colombo M.P. Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood. 101:2003;568-575.
27. De Leo A.B., Becker M., Lu L., Law L.W. Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma. Cancer Res. 53:1993;1602-1607.
28. De Visser K.E., Schumacher T.N., Kruisbeek A.M. CD8+ T cell tolerance and cancer immunotherapy. J. Immunother. 26:2003;1-11.
29. Dennis J.W., Laferte S. Oncodevelopmental expression of GlcNAcβ1,6Manα1,6Manα1-branched asparagine-linked oligosaccharides in murine tissues and human breast carcinoma. Cancer Res. 49:1989;945-950.
30. Deroo S., Muller C.P. Antigenic and immunogenic phage displayed mimotopes as substitute antigens: applications and limitations. Comb. Chem. High Throughput Screen. 4:2001;75-110.
31. Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5:1999;1289-1297.
32. Dredge K., Marriott J.B., Todryk S.M., Dalgleish A.G. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother. 51:2002;521-531.
33. Dwek M.V., Ross H.A., Streets A.J., Brooks S.A., Adam E., Titcomb A., Woodside J.V., Schumacher U., Leathem A.J. Helix pomatia agglutinin lectin-binding oligosaccharides of aggressive breast cancer. Int. J. Cancer. 95:2001;79-85.
34. Engelhard V.H., Bullock T.N., Colella T.A., Sheasley S.L., Mullins D.W. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188:2002;136-146.
35. Fausch S.C., Da Silva D.M., Eiben G.L., Le Poole I.C., Kast W.M. Hpv protein/peptide vaccines: from animal models to clinical trials. Front. Biosci. 8:2003;S81-S91.
36. Fleuridor R., Lees A., Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J. Immunol. 166:2001;1087-1096.
37. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., Davis M.M., Engleman E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA. 98:2001;8809-8814.
38. Frassanito M.A., Mayordomo J.I., De Leo R.M., Storkus W.J., Lotze M.T., De Leo A.B. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. Cancer Res. 55:1995;124-128.
39. Galli-Stampino L., Meinjohanns E., Frische K., Meldal M., Jensen T., Werdelin O., Mouritsen S. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res. 57:1997;3214-3222.
40. Ghadersohi A., Sood A.K. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin. Cancer Res. 7:2001;2731-2738.
41. Glithero A., Tormo J., Haurum J.S., Arsequell G., Valencia G., Edwards J., Springer S., Townsend A., Pao Y.L., Wormald M., Dwek R.A., Jones E.Y., Elliott T. Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity. 10:1999;63-74.
42. Gnjatic S., Atanackovic D., Matsuo M., Jager E., Lee S.Y., Valmori D., Chen Y.T., Ritter G., Knuth A., Old L.J. Cross-presentation of HLA Class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J. Immunol. 170:2003;1191-1196.
43. Goldblatt D. Conjugate vaccines [editorial]. Clin. Exp. Immunol. 119:2000;1-3.
44. Gonzalez G., Crombet T., Catala M., Mirabal V., Hernandez J.C., Gonzalez Y., Marinello P., Guillen G., Lage A. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 9:1998;431-435.
45. Gordan J.D., Vonderheide R.H. Universal tumor antigens as targets for immunotherapy. Cytotherapy. 4:2002;317-327.
46. Gorelik E., Galili U., Raz A. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev. 20:2001;245-277.
47. Graff-Dubois S., Faure O., Gross D.A., Alves P., Scardino A., Chouaib S., Lemonnier F.A., Kosmatopoulos K. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. 169:2002;575-580.
48. Grant E.P., Beckman E.M., Behar S.M., Degano M., Frederique D., Besra G.S., Wilson I.A., Porcelli S.A., Furlong S.T., Brenner M.B. Fine specificity of TCR complementarity-determining region residues and lipid antigen hydrophilic moieties in the recognition of a CD1-lipid complex. J. Immunol. 168:2002;3933-3940.
49. Grothaus M.C., Srivastava N., Smithson S.L., Kieber-Emmons T., Williams D.B., Carlone G.M., Westerink M.A. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine. 18:2000;1253-1263.
50. Hakomori S., Zhang Y. Glycosphingolipid antigens and cancer therapy. Chem. Biol. 4:1997;97-104.
51. Hanisch F.G. O-glycosylation of the mucin type. Biol. Chem. 382:2001;143-149.
52. Haupt K., Roggendorf M., Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp. Biol. Med. (Maywood). 227:2002;227-237.
53. Haurum J.S., Arsequell G., Lellouch A.C., Wong S.Y., Dwek R.A., McMichael A.J., Elliott T. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180:1994;739-744.
54. Hayakawa Y., Takeda K., Yagita H., Smyth M.J., Van Kaer L., Okumura K., Saiki I. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood. 100:2002;1728-1733.
55. Hernandez J., Garcia-Pons F., Lone Y.C., Firat H., Schmidt J.D., Langlade-Demoyen P., Zanetti M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc. Natl. Acad. Sci. USA. 99:2002;12275-12280.
56. Herve M., Maillere B., Mourier G., Texier C., Leroy S., Menez A. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Mol. Immunol. 34:1997;157-163.
57. Hiemstra H.S., van Veelen P.A., Willemen S.J., Benckhuijsen W.E., Geluk A., de Vries R.R., Roep B.O., Drijfhout J.W. Quantitative determination of TCR cross-reactivity using peptide libraries and protein databases. Eur. J. Immunol. 29:1999;2385-2391.
58. Hiraizumi S., Takasaki S., Ochuchi N., Harada Y., Nose M., Mori S., Kobata A. Altered glycosylation of membrane glycoproteins associated with human mammary carcinoma. Jpn. J. Cancer Res. 83:1992;1063-1072.
59. Hoess R., Brinkmann U., Handel T., Pastan I. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene. 128:1993;43-49.
60. Hoff S.D., Matsushita Y., Ota D.M., Cleary K.R., Yamori T., Hakomori S., Irimura T. Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. Cancer Res. 49:1989;6883-6888.
61. Hoff S.D., Irimura T., Matsushita Y., Ota D.M., Cleary K.R., Hakomori S. Metastatic potential of colon carcinoma. Expression of ABO/lewis-related antigens. Arch. Surg. 125:1990;206-209.
62. Horig H., Lee D.S., Conkright W., Divito J., Hasson H., LaMare M., Rivera A., Park D., Tine J., Guito K., Tsang K.W., Schlom J., Kaufman H.L. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49:2000;504-514.
63. Houghton A.N., Lloyd K.O. Stuck in the MUC on the long and winding road. Nat. Med. 4:1998;270-271.
64. Hsu F.D., Nielsen T.O., Alkushi A., Dupuis B., Huntsman D., Liu C.L., Van De Rijn M., Gilks C.B. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod. Pathol. 15:2002;1374-1380.
65. Hutchins W.A., Adkins A.R., Kieber-Emmons T., Westerink M.A. Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. Mol. Immunol. 33:1996;503-510.
66. Ikuta Y., Katayama N., Wang L., Okugawa T., Takahashi Y., Schmitt M., Gu X., Watanabe M., Akiyoshi K., Nakamura H., Kuribayashi K., Sunamoto J., Shiku H. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood. 99:2002;3717-3724.
67. Jager D., Jager E., Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54:2001;669-674.
68. Jager E., Jager D., Knuth A. Clinical cancer vaccine trials. Curr. Opin. Immunol. 14:2002;178-182.
69. Jensen T., Galli S.L., Mouritsen S., Frische K., Peters S., Meldal M., Werdelin O. T cell recognition of Tn-glycosylated peptide antigens. Eur. J. Immunol. 26:1996;1342-1349.
70. Jensen T., Hansen P., Galli S.L., Mouritsen S., Frische K., Meinjohanns E., Meldal M., Werdelin O. Carbohydrate and peptide specificity of MHC class II-restricted T cell hybridomas raised against an O-glycosylated self peptide. J. Immunol. 158:1997;3769-3778.
71. Jones R.C., Kelley M., Gupta R.K., Nizze J.A., Yee R., Leopoldo Z., Qi K., Stern S., Morton D.L. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann. Surg. Oncol. 3:1996;437-445.
72. Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., Xing P.X., Jamieson G., Pietersz G., Tait B., Broadbent R., Thynne G., McKenzie I.F. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100:1997;2783-2792.
73. Kastrup I.B., Stevanovic S., Arsequell G., Valencia G., Zeuthen J., Rammensee H.G., Elliott T., Haurum J.S., Sun Y., Hwang Y., Nahm M.H. Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens. 56:2000;129-135.
74. Kieber-Emmons T., Luo P., Qiu J., Agadjanyan M., Carey L., Hutchins W., Westerink M.A., Steplewski Z. Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. Hybridoma. 16:1997;3-10.
75. Kieber-Emmons T., Luo P., Qiu J., Chang T.Y., O I., Blaszczyk-Thurin M., Steplewski Z. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat. Biotechnol. 17:1999;660-665.
76. Kieber-Emmons T., Monzavi-Karbassi B., Wang B., Luo P., Weiner D.B. Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J. Immunol. 165:2000;623-627.
77. Kjonniksen I., Rye P.D., Fodstad O. Helix pomatia agglutinin binding in human tumour cell lines: correlation with pulmonary metastases in nude mice. Br. J. Cancer. 69:1994;1021-1024.
78. Klade C.S. Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 4:2002;216-223.
79. Konno A., Hoshino Y., Terashima S., Motoki R., Kawaguchi T. Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis. Clin. Exp. Metastasis. 19:2002;61-70.
80. Le Gal F.A., Prevost-Blondel A., Lengagne R., Bossus M., Farace F., Chaboissier A., Gras-Masse H., Engelhard V.H., Guillet J.G., Gahery-Segard H. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinical study. Int. J. Cancer. 98:2002;221-227.
81. Le Naour F. Contribution of proteomics to tumor immunology. Proteomics. 1:2001;1295-1302.
82. Lee D., Abeyratne A., Carson D.A., Corr M. Induction of an antigen-specific, CD1-restricted cytotoxic T lymphocyte response in vivo. J. Exp. Med. 187:1998;433-438.
83. Linardakis E., Bateman A., Phan V., Ahmed A., Gough M., Olivier K., Kennedy R., Errington F., Harrington K.J., Melcher A., Vile R. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res. 62:2002;5495-5504.
84. Losch F.O., Muller R., Mutschler B., Neri D., Natali P.G., Reth M., Carsetti R. Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain. Int. J. Cancer. 103:2003;399-407.
85. Loukas A., Maizels R.M. Helminth C-type lectins and host-parasite interactions. Parasitol. Today. 16:2000;333-339.
86. Luo P., Agadjanyan M., Qiu J., Westerink M.A., Steplewski Z., Kieber-Emmons T. Antigenic and immunological mimicry of peptide mimotopes of Lewis carbohydrate antigens. Mol. Immunol. 35:1998;865-879.
87. Luo P., Canziani G., Cunto-Amesty G., Kieber-Emmons T. A molecular basis for functional peptide mimicry of a carbohydrate antigen. J. Biol. Chem. 275:2000;16146-16154.
88. Luo L.Y., Herrera I., Soosaipillai A., Diamandis E.P. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br. J. Cancer. 87:2002;339-343.
89. Luxton J., Shepherd P. Human papillomavirus antigens and T-cell recognition. Curr. Opin. Infect. Dis. 14:2001;139-143.
90. Machiels J.P., van Baren N., Marchand M. Peptide-based cancer vaccines. Semin. Oncol. 29:2002;494-502.
91. MacLean G.D., Reddish M., Koganty R.R., Wong T., Gandhi S., Smolenski M., Samuel J., Nabholtz J.M., Longenecker B.M. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother. 36:1993;215-222.
92. MacLean G.D., Miles D.W., Rubens R.D., Reddish M.A., Longenecker B.M. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphasis Tumor Immunol. 19:1996;309-316.
93. Mandal M., Lee K.D. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim. Biophys. Acta. 1563:2002;7-17.
94. Mandrell R.E., Apicella M.A. Lipo-oligosaccharides (LOS) of mucosal pathogens: molecular mimicry and host-modification of LOS. Immunobiology. 187:1993;382-402.
95. Marshall J.L., Hawkins M.J., Tsang K.Y., Richmond E., Pedicano J.E., Zhu M.Z., Schlom J. Phase I study in cancer patients of a replication-defective Apivox recombinant vaccine that expresses human carcinoembryogenic antigen. J. Clin. Oncol. 17:1999;332-337.
96. McKenzie I.F., Apostolopoulos V., Plebanski M., Pietersz G.A., Loveland B.E. Aspects of cancer immunotherapy. Immunol. Cell Biol. 81:2003;79-85.
97. McMahon R.F., McWilliam L.J., Clarke N.W., George N.J. Altered saccharide sequences in two groups of patients with metastatic prostatic carcinoma. Br. J. Urol. 74:1994;80-85.
98. Mehren M.M., Adams G.P., Weiner L.M. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 54:2003;343-369.
99. Meloen R.H., Puijk W.C., Slootstra J.W. Mimotopes: realization of an unlikely concept. J. Mol. Recognit. 13:2000;352-359.
100. Mitchell M.S. Cancer vaccines, a critical review - Part II. Curr. Opin. Invest. Drugs. 3:2002;150-158.
101. Mocellin S., Rossi C.R., Lise M., Marincola F.M. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol. Immunother. 51:2002;583-595.
102. Moingeon P., de Taisne C., Almond J. Delivery technologies for human vaccines. Br. Med. Bull. 62:2002;29-44.
103. Mond J.J., Lees A., Snapper C.M. T cell-independent antigens type 2 [review]. Annu. Rev. Immunol. 13:1995;655-692.
104. Monzavi-Karbassi B., Kieber-Emmons T. Current concepts in cancer vaccine strategies. Biotechniques. 30:2001;170-172. 174, 176 passim.
105. Monzavi-Karbassi B., Cunto-Amesty G., Luo P., Shamloo S., Blaszcyk-Thurin M., Kieber-Emmons T. Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int. Immunol. 13:2001;1361-1371.
106. Monzavi-Karbassi B., Cunto-Amesty G., Luo P., Kieber-Emmons T. Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. Trends Biotechnol. 20:2002;207-214.
107. Monzavi-Karbassi B., Shamloo S., Kieber-Emmons M., Jousheghany F., Luo P., Lin K.Y., Cunto-Amesty G., Weiner D.B., Kieber-Emmons T. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine. 21:2003;753-760.
108. Moran A.P., Prendergast M.M., Appelmelk B.J. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease [review]. FEMS Immunol. Med. Microbiol. 16:1996;105-115.
109. Morse M.A., Deng Y., Coleman D., Hull S., Kitrell-Fisher E., Nair S., Schlom J., Ryback M.E., Lyerly H.K. A phase I of active immunotherapy with carcinoembryogenic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastasis malignancies expressing carcinoembryogenic antigen. Clin. Cancer Res. 5:1999;1331-1338.
110. Muller S., Hanisch F.G. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J. Biol. Chem. 277:2002;26103-26112.
111. Murai H., Hara S., Ikenaka T., Goto A., Arai M., Murao S. Amino acid sequence of protein alpha-amylase inhibitor from Streptomyces griseosporeus YM-25. J. Biochem. 97:1985;1129-1133.
112. Nakagoe T., Fukushima K., Hirota M., Kusano H., Kawahara K., Ayabe H., Tomita M., Kamihira S. Immunohistochemical expression of blood group substances and related carbohydrate antigens in breast carcinoma. Jpn. J. Cancer Res. 82:1991;559-568.
113. Nizard P., Gross D.A., Babon A., Chenal A., Beaumelle B., Kosmatopoulos K., Gillet D. Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice. J. Immunother. 26:2003;63-71.
114. Oldenburg K.R., Loganathan D., Goldstein I.J., Schultz P.G., Gallop M.A. Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc. Natl. Acad. Sci. USA. 89:1992;5393-5397.
115. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:2002;227-238.
116. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M., Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94:2002;805-818.
117. Peng K.W., TenEyck C.J., Galanis E., Kalli K.R., Hartmann L.C., Russell S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62:2002;4656-4662.
118. Pulaski B.A., Clements V.K., Pipeling M.R., Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49:2000;34-45.
119. Qiu J., Luo P., Wasmund K., Steplewski Z., Kieber-Emmons T. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines [In Process Citation]. Hybridoma. 18:1999;103-112.
120. Radford K.J., Higgins D.E., Pasquini S., Cheadle E.J., Carta L., Jackson A.M., Lemoine N.R., Vassaux G. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther. 9:2002;1455-1463.
121. Ragupathi G., Coltart D.M., Williams L.J., Koide F., Kagan E., Allen J., Harris C., Glunz P.W., Livingston P.O., Danishefsky S.J. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Natl. Acad. Sci. USA. 99:2002;13699-13704.
122. Rai A.J., Zhang Z., Rosenzweig J., Shih Ie M., Pham T., Fung E.T., Sokoll L.J., Chan D.W. Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 126:2002;1518-1526.
123. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 12:2002;279-296.
124. Reece D.E., Foon K.A., Bhattacharya-Chatterjee M., Hale G.A., Howard D.S., Munn R.K., Nath R., Plummer B.A., Teitelbaum A., Phillips G.L. Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant. 26:2000;729-735.
125. Reinhard G., Marten A., Kiske S.M., Feil F., Bieber T., Schmidt-Wolf I.G. Generation of dendritic cell-based vaccines for cancer therapy. Br. J. Cancer. 86:2002;1529-1533.
126. Reyes-Sandoval A., Ertl H.C. DNA vaccines. Curr. Mol. Med. 1:2001;217-243.
127. Rieser C., Ramoner R., Holtl L., Rogatsch H., Papesh C., Stenzl A., Bartsch G., Thurnher M. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int. 63:2000;151-159.
128. Rimm D.L., Camp R.L., Charette L.A., Costa J., Olsen D.A., Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J. 7:2001;24-31.
129. Rosty C., Goggins M. Early detection of pancreatic carcinoma. Hematol. Oncol. Clin North Am. 16:2002;37-52.
130. Rush C., Mitchell T., Garside P. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways. J. Immunol. 169:2002;4951-4960.
131. Sadanaga N., Nagashima H., Mashino K., Tahara K., Yamaguchi H., Ohta M., Fujie T., Tanaka F., Inoue H., Takesako K., Akiyoshi T., Mori M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7:2001;2277-2284.
132. Sandmaier B.M., Oparin D.V., Holmberg L.A., Reddish M.A., MacLean G.D., Longenecker B.M. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J. Immunother. 22:1999;54-66.
133. Scardino A., Gross D.A., Alves P., Schultze J.L., Graff-Dubois S., Faure O., Tourdot S., Chouaib S., Nadler L.M., Lemonnier F.A., Vonderheide R.H., Cardoso A.A., Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. 168:2002;5900-5906.
134. Schmitz M., Bornhauser M., Ockert D., Rieber E.P. Cancer immunotherapy: novel strategies and clinical experiences. Trends Immunol. 23:2002;428-429.
135. Schultze J.L., Vonderheide R.H. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol. 22:2001;516-523.
136. Scott J.K., Loganathan D., Easley R.B., Gong X., Goldstein I.J. A family of concanavalin A-binding peptides from a hexapeptide epitope library. Proc. Natl. Acad. Sci. USA. 89:1992;5398-5402.
137. Seliger B., Maeurer M.J., Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today. 21:2000;455-464.
138. Sikora K., Koch G., Brenner S., Lennox E. Partial purification of tumour-specific transplantation antigens from methylcholanthrene-induced murine sarcomas by immobilized lectins. Br. J. Cancer. 40:1979;831-838.
139. Smyth M.J., Crowe N.Y., Hayakawa Y., Takeda K., Yagita H., Godfrey D.I. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 14:2002;165-171.
140. Smyth M.J., Hayakawa Y., Takeda K., Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer. 2:2002;850-861.
141. Snapper C.M., Mond J.J. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens [review]. J. Immunol. 157:1996;2229-2233.
142. Speir J.A., Abdel-Motal U.M., Jondal M., Wilson I.A. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity. 10:1999;51-61.
143. Springer G.F., Desai P.R., Tegtmeyer H., Carlstedt S.C., Scanlon E.F. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma. Cancer Biother. 9:1994;7-15.
144. Staib L., Birebent B., Somasundaram R., Purev E., Braumuller H., Leeser C., Kuttner N., Li W., Zhu D., Diao J., Wunner W., Speicher D., Beger H.G., Song H., Herlyn D. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int. J. Cancer. 92:2001;79-87.
145. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109:2002;1519-1526.
146. Sugita M., Moody D.B., Jackman R.M., Grant E.P., Rosat J.P., Behar S.M., Peters P.J., Porcelli S.A., Brenner M.B. CD1-a new paradigm for antigen presentation and T cell activation [review]. Clin. Immunol. Immunopathol. 87:1998;8-14.
147. Tatsumi T., Storkus W.J. Dendritic cell-based vaccines and therapies for cancer. Expert Opin. Biol. Ther. 2:2002;919-928.
148. Todryk S., Birchall L., Erlich R., Halanek N., Orleans-Lindsay J.K., Dalgleish A. Cytokine gene transfection for autologous and allogeneic melanoma vaccines. Adv. Exp. Med. Biol. 495:2001;365-368.
149. Touloukian C.E., Leitner W.W., Robbins P.F., Rosenberg S.A., Restifo N.P. Mining the melanosome for tumor vaccine targets: P polypeptide is a novel tumor-associated antigen. Cancer Res. 61:2001;8100-8104.
150. Toyokuni T., Hakomori S., Singhal A.K. Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates. Bioorg. Med. Chem. 2:1994;1119-1132.
151. Tsang K.Y., Zaremba S., Nieroda C.A., Zhu M.Z., Hamilton J.M., Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryogenic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:1995;982-990.
152. Tzianabos A.O., Finberg R.W., Wang Y., Chan M., Onderdonk A.B., Jennings H.J., Kasper D.L. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J. Biol. Chem. 275:2000;6733-6740.
153. Valadon P., Nussbaum G., Oh J., Scharff M.D. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. J. Immunol. 161:1998;1829-1836.
154. Varki N.M., Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. 28:2002;53-66.
155. Vonderheide R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 21:2002;674-679.
156. Westerink M.A.J., Giardina P.C., Apicella M.A., Kieber-Emmons T. Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc. Natl. Acad. Sci. USA. 92:1995;4021-4025.
157. Wirth H.P., Yang M., Karita M., Blaser M.J. Expression of the human cell surface glycoconjugates Lewis x and Lewis y by Helicobacter pylori isolates is related to cagA status. Infect. Immun. 64:1996;4598-4605.
158. Xing P.X., Michaels M., Apostolopoulos V., Prenzoska J., Bishop J., McKensie I.F.C. Phase I study of synthetic MUC1 peptides in cancer. Int. J. Oncol. 6:1995;1283-1289.
159. Zaks T.Z., Rosenberg S. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 58:1998;4902-4908.
160. Zeytin H.E., Tripathi P.K., Bhattacharya-Chatterjee M., Foon K.A., Chatterjee S.K. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Ther. 7:2000;1426-1436.
161. Zhao X.J., Cheung N.K. GD2 oligosaccharide: target for cytotoxic T lymphocytes. J. Exp. Med. 182:1995;67-74.
162. Zhao R., Loftus D.J., Appella E., Collins E.J. Structural evidence of T cell xeno-reactivity in the absence of molecular mimicry. J. Exp. Med. 189:1999;359-370.
163. Zhu M.Z., Marshall J., Cole D., Schlom J., Tsang K.Y. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6:2000;24-33.
164. Zuckier L.S., Berkowitz E.Z., Sattenberg R.J., Zhao Q.H., Deng H.F., Scharff M.D. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model [In Process Citation]. Cancer Res. 60:2000;7008-7013.